Publications in collaboration with researchers from Universidade da Coruña (40)

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Influence of BRAF and PIK3CA mutations on the efficacy of FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients with RAS wild-type metastatic colorectal carcinoma and <3 baseline circulating tumour cells: the randomised phase II VISNÚ-2 study

    ESMO open, Vol. 6, Núm. 2, pp. 100062

2019

  1. A phase 2 study of panitumumab with irinotecan as salvage therapy in chemorefractory KRAS exon 2 wild-type metastatic colorectal cancer patients

    British Journal of Cancer, Vol. 121, Núm. 5, pp. 378-383

2018

  1. A Randomized Phase II Study of Axitinib as Maintenance Therapy After First-line Treatment for Metastatic Colorectal Cancer

    Clinical Colorectal Cancer, Vol. 17, Núm. 2, pp. e323-e329

  2. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

  3. Hakai overexpression effectively induces tumour progression and metastasis in vivo

    Scientific Reports, Vol. 8, Núm. 1

2017

  1. First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

    European Journal of Cancer, Vol. 81, pp. 191-202

  2. Proteomic Analysis of the E3 Ubiquitin-Ligase Hakai Highlights a Role in Plasticity of the Cytoskeleton Dynamics and in the Proteasome System

    Journal of Proteome Research, Vol. 16, Núm. 8, pp. 2773-2788

2015

  1. Circulating miR-200c and miR-141 and outcomes in patients with breast cancer

    BMC Cancer, Vol. 15, Núm. 1

  2. Current controversies in the management of metastatic colorectal cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 659-677

2014

  1. Circulating levels of GDF15, MMP7 and miR-200c as a poor prognostic signature in gastric cancer

    Future Oncology, Vol. 10, Núm. 7, pp. 1187-1202

2012

  1. Circulating MicroRNAs: Molecular microsensors in gastrointestinal cancer

    Sensors (Switzerland), Vol. 12, Núm. 7, pp. 9349-9362

  2. Circulating miR-200c as a diagnostic and prognostic biomarker for gastric cancer

    Journal of Translational Medicine, Vol. 10, Núm. 1

  3. Evaluation of the adenocarcinoma-associated gene AGR2 and the intestinal stem cell marker LGR5 as biomarkers in colorectal cancer

    International Journal of Molecular Sciences, Vol. 13, Núm. 4, pp. 4367-4387

  4. First-line cetuximab plus capecitabine in elderly patients with advanced colorectal cancer: Clinical outcome and subgroup analysis according to KRAS status from a Spanish TTD group study

    Oncologist, Vol. 17, Núm. 3, pp. 339-345

  5. Multiple biomarker tissue arrays: A computational approach to identifying protein-protein interactions in the EGFR/ERK signalling pathway

    Journal of Molecular Signaling, Vol. 7

  6. Phase II open-label study of erlotinib in combination with gemcitabine in unresectable and/or metastatic adenocarcinoma of the pancreas: Relationship between skin rash and survival (Pantar study)

    Annals of Oncology, Vol. 23, Núm. 7, pp. 1919-1925

  7. Searching for Hif1-α interacting proteins in renal cell carcinoma

    Clinical and Translational Oncology, Vol. 14, Núm. 9, pp. 698-708

  8. State of the art in Silico tools for the study of signaling pathways in cancer

    International Journal of Molecular Sciences, Vol. 13, Núm. 6, pp. 6561-6581

2011

  1. A novel procedure for protein extraction from formalin-fixed paraffin-embedded tissues

    Proteomics, Vol. 11, Núm. 12, pp. 2555-2559